See Ping Hoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
See Ping Hoo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Chin Shern Lau
Department of Laboratory Medicine, Changi General Hospital, Singapore 529889, Singapore
4 shared publications - Tar Choon Aw
Department of Laboratory Medicine, Changi General Hospital, 2 Simei Street 3, Singapore 529889, Singapore
4 shared publications - Soon Kieng Phua
Department of Laboratory Medicine, Changi General Hospital, Singapore (S.-K.P., T.-C.A.).
3 shared publications - Y.L. Liang
Department of Laboratory Medicine, Changi General Hospital, Singapore
2 shared publications - Aung Soe Tin
Health Services Research Changi General Hospital Singapore Singapore
1 shared publication - Bing Lun Chow
Russells Hall Hospital NHS, London, UK
1 shared publication
Latest Publications
- Open Access
Evaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian Region
Introduction: SARS-CoV-2 antigen tests can complement and substitute for RT-PCR tests. Centralized laboratory automated SARS-CoV-2 antigen tests that can be scaled to process a large number COVID-19 cases simultaneously are now available. We have evaluated the new Roche Elecsys SARS-CoV-2 antigen electro-chemiluminescent immunoassay. Methods: The Roche SARS-CoV-2 antigen assay is a double-antibody sandwich electro-chemiluminescent immunoassay, which reports a cut-off index (COI) (COI ≥ 1.0 considered positive). We assessed assay precision and linearity, and confirmed the reactivity limit. We determined the assay sensitivity and specificity with a verification group (289 controls and 61 RT-PCR positive COVID-19 cases). Assay performance was also validated against the consecutive samples we received (7657 controls and 17 cases) for SARS-CoV-2 antigen testing from June to October 2021. Result: The assay had a within-run precision CV of 3.0% at COI 0.68, and a CV of 1.5% at COI 3.49. Between-run precision was 3.0% at COI 0.68 and 1.8% at COI 3.49. The assay was linear from COI 0.65 to 7.84. All 35 C50 ± 20% test results performed over 7 days were positive/negative, respectively. In the verification group, overall sensitivity was 42.6% (26/61 positive, 95% CI 30.0–55.9), and specificity was 99.7% (1/289 positive, 95% CI 98.1–100). The agreement between the SARS-CoV-2 antigen and the RT-PCR cycle threshold (Ct) count was good (r = 0.90). In cases with Ct counts ≤ 30, the antigen assay sensitivity improved to 94.7% (18/19 positive, 95% CI 74.0–99.9). In our validation group, antigen sensitivity was 62.5% (5/8 antigen positive, 95% CI 24.5–91.5) within the first week of disease onset, but no cases were reactive after the first week of disease onset. Conclusion: The Elecsys SARS-CoV-2 antigen assay has good performance within manufacturer specifications. The sensitivity of the Roche antigen assay was greatest when used in patients with lower RT-PCR Ct values (≤30) and within the first week of disease onset.
Open AccessEvaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian Region
Introduction: SARS-CoV-2 antigen tests can complement and substitute for RT-PCR tests. Centralized laboratory automated SARS-CoV-2 antigen tests that can be scaled to process a large number COVID-19 cases simultaneously are now available. We have evaluated the new Roche Elecsys SARS-CoV-2 antigen electro-chemiluminescent immunoassay. Methods: The Roche SARS-CoV-2 antigen assay is a double-antibody sandwich electro-chemiluminescent immunoassay, which reports a cut-off index (COI) (COI ≥ 1.0 considered positive). We assessed assay precision and linearity, and confirmed the reactivity limit. We determined the assay sensitivity and specificity with a verification group (289 controls and 61 RT-PCR positive COVID-19 cases). Assay performance was also validated against the consecutive samples we received (7657 controls and 17 cases) for SARS-CoV-2 antigen testing from June to October 2021. Result: The assay had a within-run precision CV of 3.0% at COI 0.68, and a CV of 1.5% at COI 3.49. Between-run precision was 3.0% at COI 0.68 and 1.8% at COI 3.49. The assay was linear from COI 0.65 to 7.84. All 35 C50 ± 20% test results performed over 7 days were positive/negative, respectively. In the verification group, overall sensitivity was 42.6% (26/61 positive, 95% CI 30.0–55.9), and specificity was 99.7% (1/289 positive, 95% CI 98.1–100). The agreement between the SARS-CoV-2 antigen and the RT-PCR cycle threshold (Ct) count was good (r = 0.90). In cases with Ct counts ≤ 30, the antigen assay sensitivity improved to 94.7% (18/19 positive, 95% CI 74.0–99.9). In our validation group, antigen sensitivity was 62.5% (5/8 antigen positive, 95% CI 24.5–91.5) within the first week of disease onset, but no cases were reactive after the first week of disease onset. Conclusion: The Elecsys SARS-CoV-2 antigen assay has good performance within manufacturer specifications. The sensitivity of the Roche antigen assay was greatest when used in patients with lower RT-PCR Ct values (≤30) and within the first week of disease onset.
- 1 October 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 296, 114224
Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms
- 1 October 2021
- Published by Elsevier in Journal of Virological Methods
- Vol. 296, 114224
Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms
- 24 May 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (9) , 1531-1537
Serum anion gap revisited: a verified reference interval for contemporary use
Background: The anion gap (AG) is often used to evaluate acid–base disorders. The reference interval for normal AG is used to differentiate between raised (gap) or normal AG (non‐gap) acidosis. Historically accepted AG values may not be valid with the evolution of modern analytical techniques and the reference interval requires revalidation.Aims: To determine the reference interval for AG based on current laboratory techniques.Methods: During a health‐screening exercise, 284 participants with no major illnesses volunteered surplus blood for analysis. The samples were tested in an internationally accredited clinical laboratory. AG was calculated by [Na+] − [Cl−] − [HCO3−] and AGK by [Na+] + [K+] − [Cl−] − [HCO3−]. The reference interval was determined at 2.5th–97.5th percentiles. Analysis was further undertaken for a subcohort of 156 individuals with no suboptimal health indicators.Results: Median age was 35 years, body mass index 23.4 kg/m2 and the glomerular filtration rate was 106 mL/min/1.73 m2. Median AG was 13 mmol/L and the reference interval for normal AG is 10–18 mmol/L with a 99% level of confidence. Statistically significant differences in AG were detected for sex, race, obesity and serum albumin, but the difference was 1 mmol/L between subgroups. The reference interval was the same for the sub‐cohort of 156 individuals. Median AGK was 17.7 mmol/L and reference interval was 14.6–22.5 mmol/L.Conclusions: The AG reference interval of 10–18 mmol/L is valid for laboratories with similar reference intervals for electrolytes. Lower values expected with current laboratory techniques were not observed. The median AG of 13 mmol/L may be used to differentiate gap acidosis, non‐gap acidosis or mixed acid–base disorders.
- 24 May 2021
- Published by Wiley in Internal Medicine Journal
- Vol. 52 (9) , 1531-1537
Serum anion gap revisited: a verified reference interval for contemporary use
Background: The anion gap (AG) is often used to evaluate acid–base disorders. The reference interval for normal AG is used to differentiate between raised (gap) or normal AG (non‐gap) acidosis. Historically accepted AG values may not be valid with the evolution of modern analytical techniques and the reference interval requires revalidation.Aims: To determine the reference interval for AG based on current laboratory techniques.Methods: During a health‐screening exercise, 284 participants with no major illnesses volunteered surplus blood for analysis. The samples were tested in an internationally accredited clinical laboratory. AG was calculated by [Na+] − [Cl−] − [HCO3−] and AGK by [Na+] + [K+] − [Cl−] − [HCO3−]. The reference interval was determined at 2.5th–97.5th percentiles. Analysis was further undertaken for a subcohort of 156 individuals with no suboptimal health indicators.Results: Median age was 35 years, body mass index 23.4 kg/m2 and the glomerular filtration rate was 106 mL/min/1.73 m2. Median AG was 13 mmol/L and the reference interval for normal AG is 10–18 mmol/L with a 99% level of confidence. Statistically significant differences in AG were detected for sex, race, obesity and serum albumin, but the difference was 1 mmol/L between subgroups. The reference interval was the same for the sub‐cohort of 156 individuals. Median AGK was 17.7 mmol/L and reference interval was 14.6–22.5 mmol/L.Conclusions: The AG reference interval of 10–18 mmol/L is valid for laboratories with similar reference intervals for electrolytes. Lower values expected with current laboratory techniques were not observed. The median AG of 13 mmol/L may be used to differentiate gap acidosis, non‐gap acidosis or mixed acid–base disorders.
- Open Access
- 1 March 2021
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 24, e00201
Performance of two rapid point of care SARS-COV-2 antibody assays against laboratory-based automated chemiluminescent immunoassays for SARS-COV-2 IG-G, IG-M and total antibodies
- 1 March 2021
- Published by Elsevier in Practical Laboratory Medicine
- Vol. 24, e00201
Open AccessPerformance of two rapid point of care SARS-COV-2 antibody assays against laboratory-based automated chemiluminescent immunoassays for SARS-COV-2 IG-G, IG-M and total antibodies
- 1 November 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 510, 760-766
Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay
- 1 November 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 510, 760-766
Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay